Al­ny­lam seeks com­pen­sa­tion from Mod­er­na and Pfiz­er in suits over patent­ed de­liv­ery of their Covid-19 vac­cines

RNAi ther­a­peu­tics jug­ger­naut Al­ny­lam Phar­ma­ceu­ti­cals on Thurs­day an­nounced that it’s su­ing and seek­ing mon­ey from both Pfiz­er and Mod­er­na re­gard­ing their use of Al­ny­lam’s biodegrad­able lipids, which have been in­te­gral to the way both com­pa­nies’ mR­NA vac­cines work.

The suits, filed in the Delaware dis­trict court, both seek “fair com­pen­sa­tion for use of its tech­nol­o­gy” but “no less than a rea­son­able roy­al­ty.” And if suc­cess­ful, the biotech will dip in­to two of the rich­est rev­enue streams the bio­phar­ma in­dus­try has ever seen.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER